Chishima Real Estate, M3, Miraca, Nippon Life, POC Clinical Research, Reprocell, Toho Holdings and Zenoaq have all scored exits after the cell therapy provider went public.

Kringle Pharma, a Japan-based biotherapeutics drug developer backed by a range of corporate investors, has floated on Tokyo Stock Exchange’s Mothers Market.

The initial public offering (IPO) was approved on November 24 and Kringle Pharma issued 7 million shares, with 87,000 set aside for the overallotment option.

Founded as an Osaka University spinout in 2001, Kringle Pharma is working on cell therapies for hitherto incurable diseases including acute spinal cord injury and amyotrophic lateral sclerosis, more commonly known as ALS.

…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn